QUOTE AND NEWS
FiercePharma  Sep 12  Comment 
Eli Lilly has harbored big hopes for its newly approved cancer fighter Cyramza. It expects it to get a string approvals, and with new data in hand, it said it will go to the FDA with an application for colon cancer in the first half of next year.
FiercePharma  Sep 12  Comment 
Since 2007, the wholesale cost for a one-month supply of insulin product Humulin has gone from about $220 to approximately $1,200, MedPage Today reports.
FierceBiotech  Sep 12  Comment 
Eli Lilly's Cyramza (ramucirumab) met its primary endpoint in a study on metastatic colorectal cancer, good news for a key cog in the drugmaker's plans to capitalize on oncology.
StreetInsider.com  Sep 12  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Lilly+%28Eli%29+%26+Co.+%28LLY%29+Reports+Cyramza+Met+Primary+Endpoint+in+Phase+III/9827805.html for the full story.
MedPage Today  Sep 11  Comment 
(MedPage Today) -- Insulin is an old drug, so why did the price of one of its most concentrated formulations, Humulin U-500, increase more than five times over the last seven years?
MedPage Today  Sep 11  Comment 
Market Intelligence Center  Sep 10  Comment 
MarketIntelligenceCenter.com's patented algorithms have identified an attractive covered-call trade on Eli Lilly and Co (LLY). Look at the Nov. '14 $65.00 covered call for a net debit in the $63.00 area. This trade has a duration of 73 days. The...
newratings.com  Sep 10  Comment 
INDIANAPOLIS (dpa-AFX) - The European Commission granted marketing authorisation for Eli Lilly and Co. (LLY) and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and...
MedPage Today  Sep 9  Comment 
(MedPage Today) -- Once-daily insulin peglispro proved non-inferior to insulin glargine (Lantus) in two of the late-stage trials in the IMAGINE program, drugmaker Eli Lilly announced.
DailyFinance  Sep 8  Comment 
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from the AMBITION study (a randomized, double-blind, multicenter study of first-line combination therapy with AMBrIsentan and Tadalafil in patients with pulmonary...
Jutia Group  Sep 4  Comment 
[PR Newswire] - INDIANAPOLIS, Sept. 4, 2014 /PRNewswire/ -- Eli Lilly and Company's (LLY) basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus®) at 26 weeks and...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki